The Living Guidelines: STEMI Anticoagulants for STEMI patients who do not go reperfusion therapy Polling Results for CLASS IIa Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class IIa Guidelines
1- It is reasonable for patients with STEMI who do not undergo reperfusion therapy to be treated with anticoagulant therapy (non-UFH regimen) for the duration of the index hospitalization, up to 8 days. (Class IIa, Level of Evidence: B)

Convenient strategies that can be used include those with LMWH (Class IIa, Level of Evidence: C) or fondaparinux (Class II a, Level of Evidence: B) using the same dosing regimens as for patients who receive fibrinolytic therapy

 AHA / ACC 2007 STEMI Guidelines for Anticoagulants as Ancillary Therapy Class IIa Recommendation 1 for Low Molecular Weight Heparin (LMWH) should be: CLASS I CLASS IIa CLASS IIb CLASS III

 AHA / ACC 2007 STEMI Guidelines for Anticoagulants as Ancillary Therapy Class IIa Recommendation 1 for Fondaparinux should be: CLASS I CLASS IIa CLASS IIb CLASS III